| Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study SE Borisov, K Dheda, M Enwerem, RR Leyet, L D'Ambrosio, R Centis, ... European Respiratory Journal 49 (5), 2017 | 384 | 2017 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 236 | 2020 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 193 | 2019 |
| Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study] MC Payen, S De Wit, C Martin, R Sergysels, I Muylle, Y Van Laethem, ... The International journal of tuberculosis and lung disease 16 (4), 558-560, 2012 | 134 | 2012 |
| Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB S Tiberi, MC Payen, G Sotgiu, L D'Ambrosio, VA Guizado, JW Alffenaar, ... European Respiratory Journal 47 (4), 1235-1243, 2016 | 124 | 2016 |
| Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB S Tiberi, G Sotgiu, L D'Ambrosio, R Centis, MA Arbex, EA Arrascue, ... European Respiratory Journal 47 (6), 1758-1766, 2016 | 98 | 2016 |
| Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study RK Lodwick, CA Sabin, K Porter, B Ledergerber, A Van Sighem, ... The Lancet 376 (9738), 340-345, 2010 | 98 | 2010 |
| Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis G Sotgiu, S Tiberi, L D'Ambrosio, R Centis, JW Alffenaar, JA Caminero, ... European Respiratory Journal 48 (5), 1503-1507, 2016 | 89 | 2016 |
| Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis N Dauby, I Muylle, F Mouchet, R Sergysels, MC Payen The Pediatric infectious disease journal 30 (9), 812-813, 2011 | 87 | 2011 |
| Lipids and AIDS J Ducobu, MC Payen Revue medicale de Bruxelles 21 (1), 11-17, 2000 | 77 | 2000 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study O Akkerman, A Aleksa, JW Alffenaar, NH Al-Marzouqi, M Arias-Guillén, ... International journal of infectious diseases 83, 72-76, 2019 | 61 | 2019 |
| Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort S Koirala, S Borisov, E Danila, A Mariandyshev, B Shrestha, N Lukhele, ... Pulmonology 27 (5), 403-412, 2021 | 53 | 2021 |
| Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and … S Tiberi, G Sotgiu, L D'Ambrosio, R Centis, MA Arbex, E Alarcon Arrascue, ... Clinical Infectious Diseases 62 (9), 1188-1190, 2016 | 48 | 2016 |
| Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium L Mekkaoui, M Hallin, F Mouchet, MC Payen, E Maillart, P Clevenbergh, ... PLoS One 16 (4), e0249734, 2021 | 37 | 2021 |
| Team approach to manage difficult-to-treat TB cases: experiences in Europe and beyond L D’Ambrosio, G Bothamley, JAC Luna, R Duarte, L Guglielmetti, ... Pulmonology 24 (2), 132-141, 2018 | 37 | 2018 |
| Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of … H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, ... Open forum infectious diseases 3 (1), ofw009, 2016 | 37 | 2016 |
| Management of MDR-TB in HIV co-infected patients in Eastern Europe: results from the TB: HIV study AMW Efsen, A Schultze, RF Miller, A Panteleev, A Skrahin, ... Journal of Infection 76 (1), 44-54, 2018 | 33 | 2018 |
| Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases MC Payen, I Muylle, O Vandenberg, V Mathys, M Delforge, ... The International Journal of Tuberculosis and Lung Disease 22 (1), 34-39, 2018 | 32 | 2018 |
| Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study SE Borisov, K Dheda, M Enwerem, R Romero Leyet, L D’Ambrosio, ... Eur Respir J 49 (5), 1700387, 2017 | 22 | 2017 |
| A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS MC Payen, S De Wit, B Sommereijns, N Clumeck Biomedicine & pharmacotherapy 51 (10), 439-445, 1997 | 21 | 1997 |
